Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on therapies for neurodegenerative and metabolic disorders, has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC, effective June 8, 2026. The six-month contract, valued at US$250,000, includes company profile creation, media distribution, digital community development, news marketing and lead generation campaigns.
The company emphasized that IR Agency LLC operates at arm's length and holds no direct or indirect equity interest in Quantum's securities. This move signals Quantum's intent to increase its market presence and investor engagement as it advances its pipeline of drug candidates.
Quantum's lead compound, Lucid-MS, developed through its wholly owned subsidiary Lucid Psycheceuticals Inc., is a patented new chemical entity designed to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis—as demonstrated in preclinical models. The company also holds a 19.84% stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which markets the OTC version of UNBUZZD(TM) at www.unbuzzd.com. Quantum retains royalty payments of 7% of sales from unbuzzd(TM) until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Additionally, Quantum retains full rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The investor relations agreement comes as Quantum continues to build its portfolio of biotech solutions for challenging conditions, including alcohol misuse disorders. The company's newsroom at https://ibn.fm/QNTM provides updates on its progress. The engagement with Stocks.news through IR Agency LLC aims to enhance Quantum's visibility among investors and the broader financial community, leveraging the agency's expertise in digital marketing and lead generation.
This partnership underscores Quantum's strategic approach to investor communications, as the company seeks to attract attention to its innovative therapies and technologies. With a focus on neurodegenerative and metabolic disorders, Quantum is positioning itself in a competitive biopharmaceutical landscape, and the new investor relations initiative could play a key role in supporting its growth trajectory.
